H.C. Wainwright raised the firm’s price target on ADMA Biologics to $7.50 from $6 and keeps a Buy rating on the shares. The company’s underlying fundamentals “demonstrate continually impressive strengthening quarter-over-quarter,” the analyst tells investors in a research note. The firm is becoming increasingly bullish on the opportunity ahead for ADMA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- ADMA Biologics announces FDA approval of sBLAs for ASCENIV, BIVIGAM
- ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
- ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
- ADMA Biologics price target raised to $10 from $9 at Mizuho
- ADMA Biologics Enhances Executive Compensation and Seeks New CFO
